DnB Asset Management’s Royalty Pharma RPRX Stock Holding History

DnB Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.29M	Buy	130,008 +37,943	+41%	+$1.97M	0.02%	406
2026 Q1	$4.42M	Buy	92,065 +2,390	+3%	+$105K	0.02%	466
2025 Q4	$3.47M	Buy	89,675 +7,374	+9%	+$281K	0.01%	520
2025 Q3	$2.9M	Buy	82,301 +5,466	+7%	+$198K	0.01%	532
2025 Q2	$2.77M	Buy	76,835 +9,381	+14%	+$311K	0.01%	512
2025 Q1	$2.1M	Sell	67,454 -3,652	-5%	-$116K	0.01%	560
2024 Q4	$1.81M	Buy	71,106 +3,033	+4%	+$80.4K	0.01%	594
2024 Q3	$1.93M	Buy	+68,073	New	+$1.89M	0.01%	579

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DnB Asset Management's RPRX Position: Q2 2026 in Review

DnB Asset Management increased its Royalty Pharma (RPRX) stake by 41% in Q2 2026, buying an estimated $1.97M and bringing the position to 130,008 shares worth $7.29M. The position accounts for 0.02% of the portfolio, ranked #406.

DnB Asset Management first reported a position in RPRX in Q3 2024 and has held it in 8 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

DnB Asset Management held 130,008 shares of Royalty Pharma worth $7.29M as of Q2 2026.
DnB Asset Management bought 37,943 Royalty Pharma shares in Q2 2026, an estimated $1.97M.
Royalty Pharma made up 0.02% of DnB Asset Management's portfolio in Q2 2026, its #406 holding.
DnB Asset Management first reported a position in Royalty Pharma in Q3 2024 and has held it in 8 quarters since.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.